Form D · Pharmaceuticals
HYPERION DEFI, INC.
Laguna Hills, CA · CIK 0001682639
Offering snapshot reported Jul 22, 2025 · SEC filing
- Reported sold
- $50M Offering amount: $50M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 20, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 22, 2025 | Initial | $49,999,999 | No comparison | 5 | SEC filing |
| Apr 7, 2020 | Initial | $5,985,000 | No comparison | 82 | SEC filing |
| Aug 14, 2017 | Initial | $6,000,000 | No comparison | 10 | SEC filing |
| Aug 24, 2016 | Initial | $4,041,337 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $3M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-552478
Represents 6% of the transaction's gross proceeds issued as 307,692 shares of preferred stock to purchase 923,076 shares of common stock and warrants to purchase 1,846,153 shares of common stock. The conversion and exercise price are both $3.25 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Chardan Capital Markets, LLC | 000120128 |
Source: Form D, filed Jul 22, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Barry Butler | Executive |
| Fred Eshelman | Director |
| Fredric Eshelman | Director |
| John Gandolfo | Executive |
| Michael Geltzeiler | Director |
| Tsontcho Ianchulev | Director, Executive |
| Rachel Jacobson | Director |
| Hyunsu Jung | Director, Executive |
| Curt Labelle | Director, Executive |
| Curt La Belle | Director |
| Kenneth Lee | Director |
| Ernest Mario | Director |
| Charles Mather | Director |
| Michael Rowe | Director, Executive |
| Ellen Strahlman | Director |
| Anthony Sun | Director |
| Shuhei Yoshida | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
23461 South Pointe Drive, Suite 390
Laguna Hills, CA, 92653
Phone: 833-393-6684
Laguna Hills, CA, 92653
Phone: 833-393-6684